Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

NCT06364423 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

132

Enrollment

NIH

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
B-Lymphocytic Leukemia, Chronic
B-Cell Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Leukemia, Acute Lymphoblastic
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Rituximab

Sponsor

National Cancer Institute (NCI)